Trial | NCT01044836  Report issue

Title

Safety and Pharmacokinetic Characteristics of HD203 in Healthy Male Volunteers
A Randomized, Double-blind, Single-dosing, Crossover Study to Compare the Safety and Pharmacokinetic Characteristics of HD203 25 mg With Those of Enbrel® Injection 25 mg After Subcutaneous Injection in Healthy Male Volunteers

  • Phase

    Phase 1

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    42
The purpose of this study is compare the safety and pharmacokinetic characteristics of HD203 with those of etanercept after subcutaneous injection in healthy male volunteers.
Study Started
Jan 31
2010
Primary Completion
Jul 31
2010
Study Completion
Aug 31
2010
Last Update
Jul 15
2014
Estimate

Biological HD203

Injectable form

Etanercept Experimental

Criteria 

Inclusion Criteria:

20 to 40 years of healthy volunteers
No Results Posted